RBC Capital downgraded Verrica Pharmaceuticals (VRCA) to Sector Perform from Outperform with a price target of $2, down from $11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals: Financial Struggles Amid Strategic Shifts
- Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring
- Verrica Pharmaceuticals reports Q3 EPS (43c), consensus (37c)
- Verrica to preset results on VP-315 at Fall Clinical Dermatology Conference
- Verrica Pharmaceuticals price target lowered to $10 from $15 at TD Cowen